Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
1 evidence topic · 1 source
QTORIN rapamycin 3.9 percent gel
Microcystic lymphatic malformations
- Manufacturer
- Palvella Therapeutics
- Regulatory submission
- NDA submitted August 2026
- Last updated